CY1120074T1 - COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF Rheumatoid Arthritis and Methods for Using It - Google Patents
COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF Rheumatoid Arthritis and Methods for Using ItInfo
- Publication number
- CY1120074T1 CY1120074T1 CY20181100213T CY181100213T CY1120074T1 CY 1120074 T1 CY1120074 T1 CY 1120074T1 CY 20181100213 T CY20181100213 T CY 20181100213T CY 181100213 T CY181100213 T CY 181100213T CY 1120074 T1 CY1120074 T1 CY 1120074T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- rheumatoid arthritis
- compositions
- therapeutic treatment
- dmard
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C19/00—Alloys based on nickel or cobalt
- C22C19/03—Alloys based on nickel or cobalt based on nickel
- C22C19/05—Alloys based on nickel or cobalt based on nickel with chromium
- C22C19/058—Alloys based on nickel or cobalt based on nickel with chromium without Mo and W
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21D—WORKING OR PROCESSING OF SHEET METAL OR METAL TUBES, RODS OR PROFILES WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21D22/00—Shaping without cutting, by stamping, spinning, or deep-drawing
- B21D22/02—Stamping using rigid devices or tools
- B21D22/022—Stamping using rigid devices or tools by heating the blank or stamping associated with heat treatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B21—MECHANICAL METAL-WORKING WITHOUT ESSENTIALLY REMOVING MATERIAL; PUNCHING METAL
- B21J—FORGING; HAMMERING; PRESSING METAL; RIVETING; FORGE FURNACES
- B21J1/00—Preparing metal stock or similar ancillary operations prior, during or post forging, e.g. heating or cooling
- B21J1/06—Heating or cooling methods or arrangements specially adapted for performing forging or pressing operations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C19/00—Alloys based on nickel or cobalt
- C22C19/03—Alloys based on nickel or cobalt based on nickel
- C22C19/05—Alloys based on nickel or cobalt based on nickel with chromium
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
- C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
- C22F1/10—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of nickel or cobalt or alloys based thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mechanical Engineering (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Rheumatology (AREA)
- Thermal Sciences (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους θεραπευτικής αγωγής και βελτίωσης των συμπτωμάτων της ρευματοειδούς αρθρίτιδας χρησιμοποιώντας ένα αντίσωμα ή θραύσμα δέσμευσης αντιγόνου αυτού που δεσμεύει ειδικά τον ανθρώπινο υποδοχέα ιντερλευκίνης-6 (hIL-6R) με ένα DMARD.The present invention provides compositions and methods for treating and ameliorating the symptoms of rheumatoid arthritis using an antibody or antigen-binding fragment thereof that specifically binds the human interleukin-6 (hIL-6R) receptor to a DMARD.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161545864P | 2011-10-11 | 2011-10-11 | |
EP12305889 | 2012-07-20 | ||
PCT/EP2012/070052 WO2013053751A1 (en) | 2011-10-11 | 2012-10-10 | Compositions for the treatment of rheumatoid arthritis and methods of using same |
EP12769684.7A EP2766039B1 (en) | 2011-10-11 | 2012-10-10 | Compositions for the treatment of rheumatoid arthritis and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120074T1 true CY1120074T1 (en) | 2018-12-12 |
Family
ID=61906559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100213T CY1120074T1 (en) | 2011-10-11 | 2018-02-22 | COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF Rheumatoid Arthritis and Methods for Using It |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2021167333A (en) |
KR (1) | KR20200039028A (en) |
CY (1) | CY1120074T1 (en) |
HR (1) | HRP20180299T1 (en) |
IL (2) | IL265949B (en) |
SG (1) | SG10201914052TA (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102585002A (en) * | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | High affinity antibodies to human il-6 receptor |
JO3030B1 (en) * | 2009-06-26 | 2016-09-05 | Galapagos Nv | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases |
JO3417B1 (en) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
-
2012
- 2012-10-10 KR KR1020207010000A patent/KR20200039028A/en not_active IP Right Cessation
- 2012-10-10 SG SG10201914052TA patent/SG10201914052TA/en unknown
-
2018
- 2018-02-19 HR HRP20180299TT patent/HRP20180299T1/en unknown
- 2018-02-22 CY CY20181100213T patent/CY1120074T1/en unknown
-
2019
- 2019-04-10 IL IL265949A patent/IL265949B/en unknown
-
2021
- 2021-07-06 JP JP2021111885A patent/JP2021167333A/en active Pending
- 2021-09-26 IL IL286709A patent/IL286709A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG10201914052TA (en) | 2020-03-30 |
KR20200039028A (en) | 2020-04-14 |
IL265949A (en) | 2019-05-30 |
IL265949B (en) | 2021-10-31 |
IL286709A (en) | 2021-10-31 |
JP2021167333A (en) | 2021-10-21 |
HRP20180299T1 (en) | 2018-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021015309A (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same. | |
CY1119445T1 (en) | ANTIBODIES AGAINST HUMAN GDF8 | |
CY1122754T1 (en) | METHODS OF INDUCING NASAL POLYPODYSIS BY ADMINISTERING AN IL-4R ANTAGONIST | |
CY1120359T1 (en) | STABLE PHARMACEUTICAL FORMS OF ANTIBODIES AGAINST HUMAN RELIABLE PD-1 RECEPTION DEATH AND RELATED TREATMENTS | |
CY1122593T1 (en) | ANTI-CD40 ANTIBODIES AND USES THEREOF | |
CY1124307T1 (en) | PHARMACEUTICAL COMPOSITION, METHODS OF THERAPY AND USES THEREOF | |
CY1123145T1 (en) | ANTI-CD40 ANTIBODIES | |
BR112013021863A2 (en) | il-6 receptor antibodies and methods of use | |
CY1124787T1 (en) | ANTI-GITR ANTIBODIES AND METHODS OF USING THEM | |
MX2020011993A (en) | Compositions for the treatment of rheumatoid arthritis and methods of using same. | |
CY1121360T1 (en) | DNA-PK INHIBITORS | |
CY1122073T1 (en) | ANTIBODY MOLECULES SPECIFIC FOR HUMAN OX40 | |
CY1121906T1 (en) | METHOD OF TREATING ATOPIC DERMATITIS BY ADMINISTERING AN ANTAGONIST OF IL-4R | |
CY1119942T1 (en) | METHODS OF TREATMENT OF PHILOSOPHY USING IL-17 COMPETITORS | |
CY1123051T1 (en) | TAPENTADOL FOR THE PREVENTION AND TREATMENT OF DEPRESSION AND ANXIETY | |
CY1113640T1 (en) | METHODS FOR TREATMENT OF Rheumatoid Arthritis | |
EA201791693A1 (en) | HETERODIMERNY IMMUNOHLOBULINS | |
CY1120751T1 (en) | RORC2 HETERODYCYLOLEL INHIBITORS AND METHODS OF USING THEM | |
CY1121436T1 (en) | DOSAGE FOR JANUS CHINESE INHIBITORS (JAK) | |
CY1120877T1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABDOMINAL | |
CY1124238T1 (en) | USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS DEFECTIVE | |
EA201590359A1 (en) | TREATMENT OF RHEUMATOID ARTHRITIS | |
BR112013001062A2 (en) | humanized antibodies targeting the cadherin-11 ec1 domain and related compositions and methods | |
CY1123116T1 (en) | THERAPEUTIC TREATMENT OF AUTOIMMUNE DISORDERS WITH CD154 ANTIBODIES | |
MX2014013678A (en) | Agents for influenza neutralization. |